1.Medication errors among nurses in teaching hospitals in the west of Iran: what we need to know about prevalence, types, and barriers to reporting
Afshin FATHI ; Mohammad HAJIZADEH ; Khalil MORADI ; Hamed ZANDIAN ; Maryam DEZHKAMEH ; Shima KAZEMZADEH ; Satar REZAEI
Epidemiology and Health 2017;39(1):2017022-
OBJECTIVES: This study aimed to examine the prevalence and types of medication errors (MEs), as well as barriers to reporting MEs, among nurses working in 7 teaching hospitals affiliated with Kermanshah University of Medical Sciences in 2016.METHODS: A convenience sampling method was used to select the study participants (n=500 nurses). A self-constructed questionnaire was employed to collect information on participants’ socio-demographic characteristics (10 items), their perceptions about the main causes of MEs (31 items), and barriers to reporting MEs to nurse managers (11 items). Data were collected from September 1 to November 30, 2016. Negative binomial regression was used to identify the main predictors of the frequency of MEs among nurses.RESULTS: The prevalence of MEs was 17.0% (95% confidence interval, 13.7 to 20.3%). The most common types of MEs were administering medications at the wrong time (24.0%), dosage errors (16.8%), and administering medications to the wrong patient (13.8%). A heavy workload and the type of shift work were considered to be the main causes of MEs by nursing staff. Our findings showed that 45.0% of nurses did not report MEs. A heavy workload due to a high number of patients was the most important reason for not reporting MEs (mean score, 3.57±1.03) among nurses. Being male, having a second unrelated job, and fixed shift work significantly increased MEs among nurses (p=0.001).CONCLUSIONS: Our study documented a high prevalence of MEs among nurses in the west of Iran. A heavy workload was considered to be the most important barrier to reporting MEs among nurses. Thus, appropriate strategies (e.g., reducing the nursing staff workload) should be developed to address MEs and improve patient safety in hospital settings in Iran.
Hospitals, Teaching
;
Humans
;
Iran
;
Male
;
Medication Errors
;
Methods
;
Nurse Administrators
;
Nursing Staff
;
Patient Safety
;
Prevalence
2.Medication errors among nurses in teaching hospitals in the west of Iran: what we need to know about prevalence, types, and barriers to reporting.
Afshin FATHI ; Mohammad HAJIZADEH ; Khalil MORADI ; Hamed ZANDIAN ; Maryam DEZHKAMEH ; Shima KAZEMZADEH ; Satar REZAEI
Epidemiology and Health 2017;39(1):e2017022-
OBJECTIVES: This study aimed to examine the prevalence and types of medication errors (MEs), as well as barriers to reporting MEs, among nurses working in 7 teaching hospitals affiliated with Kermanshah University of Medical Sciences in 2016. METHODS: A convenience sampling method was used to select the study participants (n=500 nurses). A self-constructed questionnaire was employed to collect information on participants’ socio-demographic characteristics (10 items), their perceptions about the main causes of MEs (31 items), and barriers to reporting MEs to nurse managers (11 items). Data were collected from September 1 to November 30, 2016. Negative binomial regression was used to identify the main predictors of the frequency of MEs among nurses. RESULTS: The prevalence of MEs was 17.0% (95% confidence interval, 13.7 to 20.3%). The most common types of MEs were administering medications at the wrong time (24.0%), dosage errors (16.8%), and administering medications to the wrong patient (13.8%). A heavy workload and the type of shift work were considered to be the main causes of MEs by nursing staff. Our findings showed that 45.0% of nurses did not report MEs. A heavy workload due to a high number of patients was the most important reason for not reporting MEs (mean score, 3.57±1.03) among nurses. Being male, having a second unrelated job, and fixed shift work significantly increased MEs among nurses (p=0.001). CONCLUSIONS: Our study documented a high prevalence of MEs among nurses in the west of Iran. A heavy workload was considered to be the most important barrier to reporting MEs among nurses. Thus, appropriate strategies (e.g., reducing the nursing staff workload) should be developed to address MEs and improve patient safety in hospital settings in Iran.
Hospitals, Teaching*
;
Humans
;
Iran*
;
Male
;
Medication Errors*
;
Methods
;
Nurse Administrators
;
Nursing Staff
;
Patient Safety
;
Prevalence*
3.Erratum to: Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.
Mohammad Hassan HEIDARI ; Abolfazl MOVAFAGH ; Mohammad Amin ABDOLLAHIFAR ; Shabnam ABDI ; Mohamadreza Mashhoudi BAREZ ; Hadi AZIMI ; Afshin MORADI ; Amin BAGHERI ; Matineh HEIDARI ; Jafar HESSAM MOHSENI ; Maryam TADAYON ; Hoda MIRSAFIAN ; Mahdi GHATREHSAMANI
Anatomy & Cell Biology 2017;50(2):162-162
No abstract available.
4.Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.
Mohammad Hassan HEIDARI ; Abolfazl MOVAFAGH ; Mohammad Amin ABDOLLAHIFAR ; Shabnam ABDI ; Mohamadreza Mashhoudi BAREZ ; Hadi AZIMI ; Afshin MORADI ; Amin BAGHERI ; Matineh HEIDARI ; Jafar HESSAM MOHSENI ; Maryam TADAYON ; Hoda MIRSAFIAN ; Mahdi GHATREHSAMANI
Anatomy & Cell Biology 2017;50(1):69-72
Prostate cancer is the most common cancer type in men and is the second cause of death, due to cancer, in patients over 50, after lung cancer. Prostate specific antigen (PSA) is a widely used tumor marker for prostate cancer. Recently, PSA is discovered in non-prostatic cancer tissues in men and women raising doubts about its specificity for prostatic tissues. PSA exists in low serum level in healthy men and in higher levels in many prostate disorders, including prostatitis and prostate cancer. Thus, a supplementary tumor marker is needed to accurately diagnose the cancer and to observe the patient after treatment. Recently, soluble human leukocyte antigen-G (sHLA-G) has been introduced as a new tumor marker for different cancer types, including colorectal, breast, lung, and ovary. The present descriptive-experimental study was carried out including patients with malignant prostate tumor, patients with benign prostate tumor, and a group of health men as the control group, as judged by an oncologist as well as a pathologist. After sterile blood sampling, sHLA-G was measured by enzyme-linked immunosorbent assay in each group. The data was then analyzed using one-way ANOVA. P≤0.05 was considered as statistically significant. The results showed that the mean of sHLA-G level was high in patients. Also, it was found that there was a significant difference in sHLA serum level between the three groups. The data revealed that sHLA-G can be a novel supplementary tumor marker in addition to PSA to diagnose prostate cancer.
Breast
;
Cause of Death
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Leukocytes
;
Lung
;
Lung Neoplasms
;
Male
;
Ovary
;
Prostate*
;
Prostate-Specific Antigen
;
Prostatic Neoplasms*
;
Prostatitis
;
Sensitivity and Specificity